Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 30, 1999

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Leukemia
Interventions
BIOLOGICAL

Dose Level 1

Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5

BIOLOGICAL

Dose Level 2

Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5

BIOLOGICAL

Dose Level 3

Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 4.2 x 10\^7

Trial Locations (3)

77030

Texas Children's Hospital GCRC, Houston

Texas Children's Hospital, Houston

The Methodist Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00058799 - Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine | Biotech Hunter | Biotech Hunter